Drug unit errors
J-code claims denied or underpaid for unit miscalculation. We convert dosages to billing units per code.
Home / Specialties / Hematology
Hematology bills complex E/M, infusions and injections, and expensive drugs, often alongside oncology. The revenue risk is in drug billing: J-codes, units, wastage, prior authorization and the buy-and-bill economics that decide whether an infusion makes money or loses it.
General billers treat every specialty the same. These are the rules, code families and payer habits that decide whether hematology claims pay the first time.
Every denial gets a root cause, a fix and a feedback loop, so the same denial stops coming back.
J-code claims denied or underpaid for unit miscalculation. We convert dosages to billing units per code.
Claims denied for missing JW or JZ. Applied per payer rule at the scrubber.
Administration codes denied for wrong initial and sequential logic. We apply the hierarchy from the infusion record.
A dedicated team that already knows your payers' rules, plus the reporting to prove it is working. Credentialing for new hematology providers runs in the same system, tracked live in your client portal.
The full revenue cycle as standard for hematology practices, priced on what we collect for you. Take all of it, or start with one piece such as AR recovery or credentialing.
Drug units. A J-code's billing unit rarely matches the clinical dose, and miscalculation underpays or denies the claim. We convert every dose.
Yes. We document wastage and apply JW or JZ as each payer requires.
Yes. We report reimbursement against drug cost by agent so you can see which infusions are worth providing in-office.
Send us your specialty, provider count and monthly claim volume through the quote form and we will come back with a written proposal. Transitions run alongside your current billing so nothing is dropped, and credentialing for new hematology providers can start at the same time.
Send us a snapshot of your current billing and we will come back with a quote and a realistic view of recoverable revenue.